KLRC1 and post-transplant lymphoproliferative disease: The similar cytotoxicity of CD56dimNKG2A+KIR− NK cells from IM and PTLD patients argues against different NKG2A mediated licensing due to different HLA class I distribution in the two patient cohorts (28).